Why India Must Turn Its Attention to Infertancy

India crossed a demographic threshold last year – the Sample Registration System put the total fertility rate at 1.9, well under the 2.1 replacement level. In some states the numbers look even bleaker: Delhi records 1.2, while Kerala, Tamil Nadu and West Bengal hover around 1.3. That’s a stark contrast to the 5.2 children per woman we saw back in 1971.

Governments have responded with cash‑incentives – Andhra Pradesh, for example, now hands out ₹30,000 for a third child and ₹40,000 for a fourth, and other states are mulling similar schemes. The idea is simple: give families a financial nudge.

But the second reality is harsher. Ayushman Bharat – the world’s biggest publicly‑funded health‑assurance programme – does not cover IVF or any other assisted‑reproductive technology in most states. Private insurers aren’t any kinder; infertility sits alongside cosmetic surgery in the list of exclusions.

Sure, education, contraception and rising living costs explain a chunk of the decline. A lot of the slowdown is a conscious choice, and that’s largely good news. Yet the World Health Organization estimates that about 17.5% of adults – roughly one in six – experience infertility at some point, and the figure barely shifts between rich and poor nations. In India, that translates to 15‑20% of couples who simply cannot conceive.

When policy debates treat every “missing” birth as a matter of preference, they miss the nuance between a deliberate decision and a medical diagnosis. Without that distinction, any programme we design ends up shooting in the dark.

The price tag of a single IVF cycle today ranges from ₹1.2 lakh to ₹3 lakh, and that’s before a second attempt. Public coverage is essentially non‑existent; private policies are riddled with two‑ to four‑year waiting periods and sub‑limits that cap a ₹10 lakh plan at a meagre ₹50,000. Imagine a 36‑year‑old woman told she must wait four years before her insurer will even consider a claim – it reads like a polite refusal, because ovarian reserve simply doesn’t wait.

That financial wall pushes couples into a clinical corner. Those who can scrape together enough for one attempt often demand the most aggressive protocol and balk at single‑embryo transfer, convinced that two embryos double their chances. The inevitable delay in gathering money becomes the only variable that can’t be reclaimed once treatment starts.

In the long run, the economics swing back the other way. Twins, pre‑term births and neonatal intensive‑care costs far outweigh the savings made on the IVF cycle itself. We save on treatment, then spend a fortune in the NICU.

If a state is ready to hand out cash for a fourth child, extending a modest subsidy for two IVF cycles to a couple who can’t have a first child isn’t a massive leap.

Technology, however, is already shifting the balance. Vitrification turned embryo freezing from a gamble into routine, meaning a single egg retrieval can now fuel several frozen‑embryo transfers. Time‑lapse incubation lets embryologists watch development without disturbing the culture, while AI‑assisted selection is beginning to bring consistency to what used to be a largely subjective judgment. Electronic witnessing has made the once‑rare misidentification of embryos almost a thing of the past.

All of this translates to fewer cycles needed per successful birth – and, consequently, a lower cost per baby. A couple that a decade ago might have required two or three full stimulations can now often achieve pregnancy with one retrieval followed by two frozen transfers. The case for funding, therefore, gets stronger, not weaker. The treatment we’re asking insurers and public schemes to cover today is safer, more effective and far more predictable than the one they dismissed ten years ago. Science has moved; financing has not.

Another blind spot is the professional standing of clinical embryologists. Radiographers, medical lab technologists and physiotherapists enjoy recognised professional categories. Embryology, a younger discipline, still lacks a unified statutory identity. That’s not a judgement on anyone’s competence – the field simply outpaced the regulatory frameworks, a familiar story for any emerging specialty.

India is not short of embryology education. Master’s programmes have multiplied and thousands now hold the qualification. Yet there is no standardised curriculum, no mandated minimum of supervised procedures, no compulsory case logs, and no practical exit assessment. In practice, laboratories may hire someone with a degree but uneven hands‑on skill, and there’s little that forces employers to verify those competencies.

What we need is a two‑pronged approach: first, recognise infertility unequivocally as a medical disease and cover a defined course of treatment under public and private schemes; second, grant clinical embryology the professional status and certification standards that comparable roles already enjoy.

India spent half a century persuading its citizens to have fewer children. It succeeded. Now the harder challenge is ensuring that the couples who do want a child can actually have one – without drowning in cost or navigating a regulatory maze.